NEWS
CONFERENCES
MEDIA
PUBLICATIONS
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
SUBSCRIBE

Opinion|Videos|June 20, 2024

DESTINY-Breast04: Trastuzumab Deruxtecan in HR+/HER2-Low Metastatic Breast Cancer

Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD

Breast cancer specialists review key efficacy and safety data from the DESTINY-Breast04 trial investigating trastuzumab deruxtecan in patients with HR+/HER2-low metastatic breast cancer.

Episodes in this series

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer

EP. 1 Treatment Sequencing and Unmet Needs in HR+/HER2-Low Metastatic Breast Cancer

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer

EP. 2 DESTINY-Breast04: Trastuzumab Deruxtecan in HR+/HER2-Low Metastatic Breast Cancer

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer

EP. 3 Best Candidates for HER2-Directed ADCs in HR+/HER2-Low Metastatic Breast Cancer

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer

EP. 4 Insights on T-DXd and Emerging Research on ADCs in HR+/HER2-Low Breast Cancer

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer

EP. 5 Emerging Pathways and Role of TROP2-Directed ADCs in HR+/HER2- mBC

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer

EP. 6 TROPION-Breast01: Dato-DXd in HR+/HER2- Metastatic Breast Cancer

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer

EP. 7 TROPiCS-02: Sacituzumab Govitecan in HR+/HER2- Metastatic or Locally Recurrent Breast Cancer

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer

EP. 8 Clinical Utilization of TROP2-Directed Antibody-Drug Conjugates

Aditya Bardia, MD, MPH, FASCO, and Laura Huppert, MD, experts on breast cancer

EP. 9 Future of TROP2- and HER2-Directed ADCs in Breast Cancer

Video content above is prompted by the following questions:

Please review key efficacy and safety data from the DESTINY-Breast04 trial, evaluating trastuzumab deruxtecan (T-DXd) in patients with HR+, HER2-low metastatic breast cancer.
- What are the clinical implications of these data in your practice?
- What notable adverse events (AEs) have you observed in your practice?
- What mitigation strategies have been implanted in your practice to combat AEs of special interest?

Newsletter

Stay up to date on practice-changing data in community practice.

Related Content

Phase 2 Presurgical Breast Cancer Trial Resumes After Dosing Pause for Skin Toxicity

BySabrina Serani

July 16th 2026

Screening Gaps Among Sexual and Gender Minorities Shown in New US Data

BySabrina Serani

July 16th 2026

FDA Approves Gedatolisib for HR+/HER2−, PIK3CA Wild-Type Advanced Breast Cancer

BySabrina Serani

July 14th 2026

Flavonoid-Rich Diet Tied to Lower Breast Cancer Risk

BySabrina Serani

July 13th 2026

Recurrence Score Elevated in Breast Cancers Diagnosed Within 3 Years Postpartum

BySabrina Serani

July 12th 2026

Latest CME

Wisconsin Association of Hematology and Oncology

Wisconsin Association of Hematology and Oncology

3 Sessions are Available!

Indiana Oncology Society

Indiana Oncology Society

2 Sessions are Available!

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

South Carolina Oncology Society

South Carolina Oncology Society

2 Sessions are Available!

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Establishing the Rationale for ADC and ICI Combinations in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Kamel Abou Hussein, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Sara A. Hurvitz, MD, FACP; Shaina Rozell, MD, MPH

Washington State Medical Oncology Society

Washington State Medical Oncology Society

1 Session is Available!

Kansas Society of Clinical Oncology

Kansas Society of Clinical Oncology

1 Session is Available!

24th Annual International Congress on the Future of Breast Cancer® East

24th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Arizona Clinical Oncology Society

Arizona Clinical Oncology Society

1 Sessions is Available!

Arkansas Association of Cancer Professionals

Arkansas Association of Cancer Professionals

2 Sessions are Available!

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

9th Annual School of Nursing Oncology™

9th Annual School of Nursing Oncology™

Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO; Beth Sandy, MSN, CRNP, FAPO; Lindsay Adkins, MSN, FNP-BC, BMTCN; Jeneth Aquino, DNP, FNP-BC; Casey Gormley, MSN, FNP-C, AOCNP; Heather J. Jackson, PhD, FNP-BC; Kelsey Martin, AG-ACNP-BC, AOCNP; Nerina T. McDonald, PA-C; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Faith A. Mutale, DNP, CRNP; Tiffany Richards, PhD, ANP-BC, AOCNP; Emily Skotte, DNP, MSN, ACNP-BC; Leslie Smith, DNP, RN, APRN-CNS, AOCNS, BMTCN; Saneese Stephen, PA-C, MPAS; Sara M. Tinsley-Vance, PhD, APRN, AOCN

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; Cynthia X. Ma, MD, PhD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Tiffany A. Traina, MD, FASCO; Kevin Kalinsky, MD MS, FASCO; Mark E. Robson, MD, FASCO; Rebecca Shatsky, MD

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm

Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC

On-Body Injector Technology Streamlines Subcutaneous Myeloma Therapy

Understanding the Sequencing Decisions in mCRPC After Progression on ADT/ARPI

First Patients Dosed With TLX597-Tx in Trial for mHSPC